Suppr超能文献

食管刷拭物的大规模平行测序可基于非整倍体对 Barrett 食管患者进行分类。

Massively Parallel Sequencing of Esophageal Brushings Enables an Aneuploidy-Based Classification of Patients With Barrett's Esophagus.

机构信息

Department of Oncology, the Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; The Ludwig Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Department of Medicine, Case Western Reserve University, Cleveland, Ohio.

出版信息

Gastroenterology. 2021 May;160(6):2043-2054.e2. doi: 10.1053/j.gastro.2021.01.209. Epub 2021 Jan 22.

Abstract

BACKGROUND & AIMS: Aneuploidy has been proposed as a tool to assess progression in patients with Barrett's esophagus (BE), but has heretofore required multiple biopsies. We assessed whether a single esophageal brushing that widely sampled the esophagus could be combined with massively parallel sequencing to characterize aneuploidy and identify patients with disease progression to dysplasia or cancer.

METHODS

Esophageal brushings were obtained from patients without BE, with non-dysplastic BE (NDBE), low-grade dysplasia (LGD), high-grade dysplasia (HGD), or adenocarcinoma (EAC). To assess aneuploidy, we used RealSeqS, a technique that uses a single primer pair to interrogate ∼350,000 genome-spanning regions and identify specific chromosome arm alterations. A classifier to distinguish NDBE from EAC was trained on results from 79 patients. An independent validation cohort of 268 subjects was used to test the classifier at distinguishing patients at successive phases of BE progression.

RESULTS

Aneuploidy progression was associated with gains of 1q, 12p, and 20q and losses on 9p and 17p. The entire chromosome 8q was often gained in NDBE, whereas focal gain of 8q24 was identified only when there was dysplasia. Among validation subjects, a classifier incorporating these features with a global measure of aneuploidy scored positive in 96% of EAC, 68% of HGD, but only 7% of NDBE.

CONCLUSIONS

RealSeqS analysis of esophageal brushings provides a practical and sensitive method to determine aneuploidy in BE patients. It identifies specific chromosome changes that occur early in NDBE and others that occur late and mark progression to dysplasia. The clinical implications of this approach can now be tested in prospective trials.

摘要

背景与目的

非整倍体被认为是评估 Barrett 食管(BE)患者进展的一种工具,但迄今为止需要多次活检。我们评估了是否可以将广泛取样食管的单个食管刷检与大规模平行测序相结合,以表征非整倍体并识别疾病进展为异型增生或癌症的患者。

方法

从无 BE、非异型增生 BE(NDBE)、低级别异型增生(LGD)、高级别异型增生(HGD)或腺癌(EAC)患者中获取食管刷检。为了评估非整倍体,我们使用了 RealSeqS,这是一种使用单个引物对来检测约 35 万个基因组覆盖区域并识别特定染色体臂改变的技术。在 79 名患者的结果上训练了用于区分 NDBE 和 EAC 的分类器。使用 268 名独立验证队列的受试者来测试分类器在区分 BE 进展各阶段患者方面的性能。

结果

非整倍体进展与 1q、12p 和 20q 的增益以及 9p 和 17p 的缺失有关。整个染色体 8q 经常在 NDBE 中获得,而只有在存在异型增生时才会发现 8q24 的局灶性增益。在验证受试者中,包含这些特征和整体非整倍体测量值的分类器在 96%的 EAC、68%的 HGD 中呈阳性,但在仅 7%的 NDBE 中呈阳性。

结论

食管刷检的 RealSeqS 分析为 BE 患者提供了一种实用且敏感的方法来确定非整倍体。它确定了在 NDBE 早期发生的特定染色体变化,以及在进展为异型增生时发生的其他变化。现在可以在前瞻性试验中测试这种方法的临床意义。

相似文献

1
Massively Parallel Sequencing of Esophageal Brushings Enables an Aneuploidy-Based Classification of Patients With Barrett's Esophagus.
Gastroenterology. 2021 May;160(6):2043-2054.e2. doi: 10.1053/j.gastro.2021.01.209. Epub 2021 Jan 22.
3
Alterations to the Esophageal Microbiome Associated with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma.
Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1687-1693. doi: 10.1158/1055-9965.EPI-19-0008. Epub 2019 Aug 29.
5
Genetic profiles of Barrett's esophagus and esophageal adenocarcinoma in Japanese patients.
Sci Rep. 2021 Sep 3;11(1):17671. doi: 10.1038/s41598-021-97249-9.
6
Barrett Esophagus Length, Nodularity, and Low-grade Dysplasia are Predictive of Progression to Esophageal Adenocarcinoma.
J Clin Gastroenterol. 2019 May/Jun;53(5):361-365. doi: 10.1097/MCG.0000000000001027.
7
Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Am J Gastroenterol. 2009 Nov;104(11):2673-80. doi: 10.1038/ajg.2009.437. Epub 2009 Jul 28.
8
Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1380-5. doi: 10.1158/1055-9965.EPI-07-2734.
9
Novel DNA Methylation Biomarker Panel for Detection of Esophageal Adenocarcinoma and High-Grade Dysplasia.
Clin Cancer Res. 2022 Sep 1;28(17):3761-3769. doi: 10.1158/1078-0432.CCR-22-0445.
10
Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
Dis Esophagus. 2017 Mar 1;30(3):1-5. doi: 10.1093/dote/dow025.

引用本文的文献

1
Identification of genome-wide copy number variation-driven subtypes for the treatment and prognostic prediction of esophageal carcinoma.
Heliyon. 2024 Sep 18;10(19):e38011. doi: 10.1016/j.heliyon.2024.e38011. eCollection 2024 Oct 15.
2
Selection forces underlying aneuploidy patterns in cancer.
Mol Cell Oncol. 2024 Jun 24;11(1):2369388. doi: 10.1080/23723556.2024.2369388. eCollection 2024.
3
Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets.
Signal Transduct Target Ther. 2024 Jun 19;9(1):149. doi: 10.1038/s41392-024-01848-7.
4
Update on Barrett Esophagus Diagnosis and Management.
Gastroenterol Hepatol (N Y). 2023 May;19(5):272-274.
5
Surveillance in Barrett's Esophagus: Challenges, Progress, and Possibilities.
Gastroenterology. 2023 Apr;164(5):707-718. doi: 10.1053/j.gastro.2023.01.031. Epub 2023 Feb 4.
6
Chromosome instability and aneuploidy as context-dependent activators or inhibitors of antitumor immunity.
Front Immunol. 2022 Jul 15;13:895961. doi: 10.3389/fimmu.2022.895961. eCollection 2022.
7
Today's Mistakes and Tomorrow's Wisdom in Development and Use of Biomarkers for Barrett's Esophagus.
Visc Med. 2022 Jun;38(3):173-181. doi: 10.1159/000521706. Epub 2022 Feb 2.
8
Barrett's esophagus: The pathomorphological and molecular genetic keystones of neoplastic progression.
Cancer Med. 2022 Jan;11(2):447-478. doi: 10.1002/cam4.4447. Epub 2021 Dec 6.
9
Evolution and progression of Barrett's oesophagus to oesophageal cancer.
Nat Rev Cancer. 2021 Nov;21(11):731-741. doi: 10.1038/s41568-021-00400-x. Epub 2021 Sep 20.
10
Artificial Intelligence in Surveillance of Barrett's Esophagus.
Cancer Res. 2021 Jul 1;81(13):3446-3448. doi: 10.1158/0008-5472.CAN-21-1511.

本文引用的文献

2
Genomic copy number predicts esophageal cancer years before transformation.
Nat Med. 2020 Nov;26(11):1726-1732. doi: 10.1038/s41591-020-1033-y. Epub 2020 Sep 7.
3
Assessing aneuploidy with repetitive element sequencing.
Proc Natl Acad Sci U S A. 2020 Mar 3;117(9):4858-4863. doi: 10.1073/pnas.1910041117. Epub 2020 Feb 19.
4
Cancer statistics, 2020.
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
6
ASGE guideline on screening and surveillance of Barrett's esophagus.
Gastrointest Endosc. 2019 Sep;90(3):335-359.e2. doi: 10.1016/j.gie.2019.05.012.
7
The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic.
Nat Genet. 2019 Mar;51(3):506-516. doi: 10.1038/s41588-018-0331-5. Epub 2019 Feb 4.
8
Comprehensive Characterization of Cancer Driver Genes and Mutations.
Cell. 2018 Apr 5;173(2):371-385.e18. doi: 10.1016/j.cell.2018.02.060.
9
Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma.
Gastroenterology. 2018 Jul;155(1):156-167. doi: 10.1053/j.gastro.2018.03.047. Epub 2018 Mar 31.
10
Evolution of Barrett's esophagus through space and time at single-crypt and whole-biopsy levels.
Nat Commun. 2018 Feb 23;9(1):794. doi: 10.1038/s41467-017-02621-x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验